Clinical Trials Browser

Phase 2 × Recruiting × Stomatitis × Clear all

Stomatitis, Mucositis

NCT06532279 2026-05-04

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Stomatitis

NCT06354712 2025-01-15

Efficacy of N-acetylcysteine in Preventing Radiotherapy-Induced Oral Mucositis in Head and Neck Cancer Patients.

Phase 2 Recruiting

50 enrolled

Stomatitis, Ulcer

NCT05966194 2024-11-15

KEVLARx

Phase 2 Recruiting

216 enrolled

Head & NeckOther

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Mouth Neoplasms, Stomatitis, Mucositis

NCT06472739 2024-06-25

The Effect of GM-CSF to Preventing Oral Mucositis for Patients With Nasopharyngeal Carcinoma Receiving Radiotherapy

Phase 2 Recruiting

138 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Stomatitis

Clinical Trials

DARENCA4

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

Efficacy of N-acetylcysteine in Preventing Radiotherapy-Induced Oral Mucositis in Head and Neck Cancer Patients.

KEVLARx

The Effect of GM-CSF to Preventing Oral Mucositis for Patients With Nasopharyngeal Carcinoma Receiving Radiotherapy